1. Volume 82, Issue 12, Pages 1297-1303 (December 2012)
Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients 
Sophie Liabeuf, Aurélie Lenglet, Lucie Desjardins, Nathalie Neirynck, Griet Glorieux, Horst-Dieter Lemke, Raymond Vanholder, Momar Diouf, Gabriel Choukroun, Ziad A. Massy 
Kidney International 
Volume 82, Issue 12, Pages (December 2012)
DOI: /ki
Copyright © 2012 International Society of Nephrology Terms and Conditions

2. Figure 1
Plasma beta-2 microglobulin levels as a function of chronic kidney disease (CKD) stage. *P< vs. control group; **P< vs. CKD stages 2 and 3; and ***P< vs. CKD stages 4 and 5.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions

3. Figure 2
Exponential relationship between plasma beta-2 microglobulin level and estimated glomerular filtration rate, predialysis chronic kidney disease stages 2–5 (n=96, r2=0.789, P<0.0001).
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions

4. Figure 3
Kaplan–Meier estimates of the probability of cardiovascular event-free survival for the subgroup of predialysis patients, as a function of median plasma beta-2 microglobulin concentration. Results were adjusted for propensity score, which included age, albumin, C-reactive protein, hemoglobin, and phosphate levels, aortic calcification score, and estimated glomerular filtration rate.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions